PURPOSE: EFdA is a potent nucleoside reverse transcriptase inhibitor (NRTI) with activity against a wide spectrum of wild-type and drug resistant HIV-1 variants. CSIC is a tight-binding non-nucleoside reverse transcriptase inhibitor (NNRTI) with demonstrated anti-HIV properties important for use in topical prevention of HIV transmission. The objective of this study was to develop and characterize film-formulated EFdA and CSIC for use as a female-controlled vaginal microbicide to prevent sexual transmission of HIV. METHODS: Assessments of EFdA- and CSIC-loaded films included physicochemical characteristics, in vitro cytotoxicity, epithelia integrity studies, compatibility with the normal vaginal Lactobacillus flora and anti-HIV bioactivity evaluations. RESULTS: No significant change in physicochemical properties or biological activity of the combination films were noted during 3 months storage. In vitro cytotoxicity and bioactivity testing showed that 50% cytotoxic concentration (CC50) of either EFdA or CSIC was several orders of magnitude higher than the 50% effective concentration (EC50) values. Film-formulated EFdA and CSIC combination showed additive inhibitory activity against wild type and drug-resistant variants of HIV. Epithelial integrity studies demonstrated that the combination vaginal film had a much lower toxicity to HEC-1A monolayers compared to that of VCF®, a commercial vaginal film product containing nonoxynol-9. Polarized ectocervical explants showed films with drug alone or in combination were effective at preventing HIV infection. CONCLUSIONS: Our data suggest that vaginal microbicide films containing a combination of the NRTI EFdA and the NNRTI CSIC have potential to prevent HIV-1 sexual transmission.
PURPOSE:EFdA is a potent nucleoside reverse transcriptase inhibitor (NRTI) with activity against a wide spectrum of wild-type and drug resistant HIV-1 variants. CSIC is a tight-binding non-nucleoside reverse transcriptase inhibitor (NNRTI) with demonstrated anti-HIV properties important for use in topical prevention of HIV transmission. The objective of this study was to develop and characterize film-formulated EFdA and CSIC for use as a female-controlled vaginal microbicide to prevent sexual transmission of HIV. METHODS: Assessments of EFdA- and CSIC-loaded films included physicochemical characteristics, in vitro cytotoxicity, epithelia integrity studies, compatibility with the normal vaginal Lactobacillus flora and anti-HIV bioactivity evaluations. RESULTS: No significant change in physicochemical properties or biological activity of the combination films were noted during 3 months storage. In vitro cytotoxicity and bioactivity testing showed that 50% cytotoxic concentration (CC50) of either EFdA or CSIC was several orders of magnitude higher than the 50% effective concentration (EC50) values. Film-formulated EFdA and CSIC combination showed additive inhibitory activity against wild type and drug-resistant variants of HIV. Epithelial integrity studies demonstrated that the combination vaginal film had a much lower toxicity to HEC-1A monolayers compared to that of VCF®, a commercial vaginal film product containing nonoxynol-9. Polarized ectocervical explants showed films with drug alone or in combination were effective at preventing HIV infection. CONCLUSIONS: Our data suggest that vaginal microbicide films containing a combination of the NRTI EFdA and the NNRTI CSIC have potential to prevent HIV-1 sexual transmission.
Authors: Atsuko Hachiya; Aaron B Reeve; Bruno Marchand; Eleftherios Michailidis; Yee Tsuey Ong; Karen A Kirby; Maxwell D Leslie; Shinichi Oka; Eiichi N Kodama; Lisa C Rohan; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos Journal: Antimicrob Agents Chemother Date: 2013-06-24 Impact factor: 5.191
Authors: Anthony S Ham; Shweta R Ugaonkar; Lianjun Shi; Karen Watson Buckheit; Howard Lakougna; Umadevi Nagaraja; Garry Gwozdz; Laurie Goldman; Patrick F Kiser; Robert W Buckheit Journal: J Pharm Sci Date: 2012-01-06 Impact factor: 3.534
Authors: Alamelu Mahalingam; Adam P Simmons; Shweta R Ugaonkar; Karen M Watson; Charlene S Dezzutti; Lisa C Rohan; Robert W Buckheit; Patrick F Kiser Journal: Antimicrob Agents Chemother Date: 2011-01-18 Impact factor: 5.191
Authors: Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos Journal: J Biol Chem Date: 2009-12-18 Impact factor: 5.157
Authors: Mahta Samizadeh; Xiaoping Zhang; Simi Gunaseelan; Antoinette G Nelson; Matthew S Palombo; Daniel R Myers; Yashveer Singh; Usha Ganapathi; Zoltan Szekely; Patrick J Sinko Journal: Drug Deliv Transl Res Date: 2016-02 Impact factor: 4.617
Authors: K M Guthrie; L Rohan; R K Rosen; S E Vargas; J G Shaw; D Katz; E M Kojic; A S Ham; D Friend; K W Buckheit; R W Buckheit Journal: Pharm Dev Technol Date: 2017-06-21 Impact factor: 3.133
Authors: Kate M Guthrie; Rochelle K Rosen; Sara E Vargas; Melissa Guillen; Arielle L Steger; Melissa L Getz; Kelley A Smith; Jaime J Ramirez; Erna M Kojic Journal: Drug Deliv Transl Res Date: 2017-10 Impact factor: 4.617
Authors: Tiantian Gong; Wei Zhang; Michael A Parniak; Phillip W Graebing; Bernard Moncla; Phalguni Gupta; Kerry M Empey; Lisa C Rohan Journal: J Pharm Innov Date: 2017-03-03 Impact factor: 2.750
Authors: Antoinette G Nelson; Xiaoping Zhang; Usha Ganapathi; Zoltan Szekely; Charles W Flexner; Andrew Owen; Patrick J Sinko Journal: J Control Release Date: 2015-08-24 Impact factor: 9.776
Authors: Tomasz Osmałek; Anna Froelich; Barbara Jadach; Adam Tatarek; Piotr Gadziński; Aleksandra Falana; Kinga Gralińska; Michał Ekert; Vinam Puri; Joanna Wrotyńska-Barczyńska; Bozena Michniak-Kohn Journal: Pharmaceutics Date: 2021-06-15 Impact factor: 6.321